A carregar...
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
Palbociclib, ribociclib, and abemaciclib have been investigated in combination with aromatase inhibitors as first-line therapy for metastatic hormone receptor-positive breast cancer (PALOMA-2, MONALEESA-2 and MONALEESA-7, MONARCH-3 trials, respectively); pivotal trials led to absolute median progres...
Na minha lista:
| Publicado no: | NPJ Breast Cancer |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group UK
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6018749/ https://ncbi.nlm.nih.gov/pubmed/29951582 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-018-0068-4 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|